Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Park-Ohio Holdings Corp. Fourth Quarter 2025 Earnings Call - Reinvestment and Deleveraging Set Stage for 2026 Growth
Park-Ohio closed 2025 with modest revenue improvement in Q4 while completing a year of heavy reinvestment and balance sheet work designed to drive 2026 momentum. Management refinanced debt, cut long t...
- Park-Ohio returned to sequential and year over year growth in Q4 2025, with consolidated net sales of $395 million, up 2% year over year.
- Full year 2025 sales were $1.6 billion, down 4% versus 2024, with weakness concentrated in North American industrial end markets.
- Management reduced long term debt by $40 million in Q4 2025 and refinanced $350 million of senior notes with new senior secured notes maturing in 2030.
- +12 more takeaways
Victoria's Secret & Co. Fourth Quarter and Fiscal 2025 Earnings Call - Path to Potential drives reacceleration, tariffs are a near-term headwind
Victoria's Secret & Co. closed fiscal 2025 with clear momentum. Q4 comp sales rose 8%, full-year comps were up 5%, and the back half acceleration translated into higher regular-price selling, expandin...
- Q4 comp sales grew 8%, full-year comps up 5%, marking the highest fourth quarter revenue since Victoria's Secret became an independent public company.
- Fiscal 2025 net sales, excluding last year’s gift card breakage benefit, were $6.553 billion, a 6% increase year-over-year.
- Fiscal 2025 adjusted operating income rose 16% to $403 million, and adjusted EPS increased 22% to $3, despite approximately $85 million of net tariff pressure in the year.
- +14 more takeaways
Victoria's Secret & Co. Fourth Quarter and Fiscal 2025 Earnings Call - Path to Potential drives bras, PINK and beauty momentum
Victoria's Secret & Co. closed fiscal 2025 with clear momentum. Q4 comps rose 8% and full-year comps were up 5%, beating top- and bottom-line guidance as the management-led Path to Potential plan tran...
- Q4 comp sales +8%; full-year comps +5%; Q4 net sales $2.27 billion, fiscal 2025 net sales $6.553 billion (ex-gift card breakage adjustment).
- Fiscal 2025 adjusted operating income $403 million (adjusted EPS $3.00), despite roughly $85 million of net tariff pressure for the year.
- Management says Path to Potential is gaining traction across four pillars: bra authority, PINK reset, beauty growth, and upgraded brand projection/go-to-market.
- +16 more takeaways
Burlington Stores Fiscal 2025 Q4 Earnings Call - Chose Margin Over Sales Amid Tariffs, Now Bullish on 2026
Burlington leaned into margin preservation in 2025, deliberately dialing down receipt plans in higher-tariff categories to protect profitability. The trade paid off: strong margin expansion and double...
- Q4 headlines: total sales +11% year-over-year, comparable store sales +4%, two-year comp stack +10% for Q4.
- Q4 profitability: adjusted EBIT margin expanded 100 basis points year-over-year; adjusted EPS $4.99, up 21% vs prior year.
- Full-year 2025: total sales +9%, comps +2%, operating margin +80 basis points, adjusted EPS growth +22% year-over-year.
- +13 more takeaways
Amprius Technologies Fourth Quarter 2025 Earnings Call - NDAA-compliant SiCore cells, $125M 2026 guide and a near-term path to positive EBITDA
Amprius closed 2025 with clear commercial momentum and a policy tailwind. Q4 revenue hit a record $25.2 million, full-year revenue was $73 million, and Q4 gross margin improved to 24% as SiCore adopti...
- Q4 2025 revenue: $25.2 million, up 18% quarter-over-quarter and 137% year-over-year; FY2025 revenue: $73 million, roughly 3x 2024.
- Q4 gross margin improved to 24%; full-year gross margin was 11% versus negative 76% in 2024, driven by increased SiCore mix and favorable product mix.
- Management reports full selection of 11 internal cell components from NDAA-compliant countries, claiming a scorecard of 11 out of 11 for country-of-origin requirements.
- +16 more takeaways
Evogene Ltd. Q4 2025 Earnings Call - Strategic pivot to ChemPass AI targeting small-molecule drug and ag-chemical discovery
Evogene used the Q4 2025 call to make the pivot plain. The company has refocused on a single computational engine, ChemPass AI, and narrowed its market targets to human health small-molecule drug disc...
- Company strategic pivot: Evogene has concentrated its R&D and commercial strategy on one computational engine, ChemPass AI, and two markets, human health small-molecule drugs and agricultural chemicals.
- ChemPass AI scale claim: the foundation model was trained or benchmarked on a 38 billion molecule universe and management reported a 90% design precision on internal benchmarks after the first Google Cloud collaboration.
- Google Cloud partnerships: first collaboration completed mid-2025, second collaboration started February 2026 to integrate advanced AI agents via Vertex AI and automate scientific workflows toward autonomous discovery.
- +12 more takeaways
Ultrapar Q4 2025 Earnings Call - Record BRL 5.5bn Operating Cash, Leverage Comfortable at 1.7x
Ultrapar closed 2025 with a headline few companies would ignore, BRL 5.5 billion of operating cash generation, a record that kept leverage comfortable at 1.7 times even after an anticipated BRL 1.1 bi...
- Operating cash generation hit a record BRL 5.5 billion in 2025, the single biggest line in the release and the main driver of financial flexibility.
- Consolidated adjusted EBITDA for Q4 2025 was BRL 1.6 billion, down 34% year-over-year due to non-recurring effects; recurring EBITDA for Q4 was BRL 1.7 billion, up 36% versus Q4 2024.
- For the full year 2025, adjusted EBITDA reached BRL 6.8 billion, up 2% year-over-year; recurring EBITDA totaled BRL 6.2 billion, a 15% increase versus 2024.
- +13 more takeaways
Ciena Fiscal Q1 2026 Earnings Call - Record demand lifts revenue and backlog to $7B, supply to constrain fulfillment into 2027
Ciena reported a blowout fiscal Q1 2026, with record revenue of $1.43 billion, adjusted gross margin of 44.7%, and adjusted EPS of $1.35. Orders were “incredibly strong,” lifting backlog by about $2 b...
- Revenue hit a record $1.43 billion in fiscal Q1 2026, at the top end of guidance, up 33% year-over-year.
- Adjusted gross margin came in at 44.7% for the quarter, ahead of expectations and approaching management’s 45% milestone.
- Adjusted EPS was $1.35, more than double Q1 a year ago, with adjusted net income of $197 million.
- +16 more takeaways
ImmuCell Corporation Q4 2025 Earnings Call - Pivot to First Defense and manufacturing scale lifts margins despite Re-Tain write-downs
ImmuCell closed 2025 with $27.6 million in product sales, a modest full year revenue gain of 4.3% and a clear strategic reset. Management pivoted decisively to the First Defense franchise, resolved a ...
- Company pivoted to focus exclusively on the First Defense franchise and paused investment in the Re-Tain subclinical mastitis program in December 2025.
- Full year product sales were $27.6 million in 2025, up 4.3% versus 2024; Q4 product sales were $7.6 million, down 1.6% year-over-year.
- Domestic Q4 sales rose 8.7% year-over-year to about $7.0 million; international Q4 sales fell to roughly $600,000, about 8% of Q4 sales, primarily due to Canadian order timing.
- +12 more takeaways
Altimmune Q4 2025 Earnings Call - Pemvidutide set for FDA-aligned global 1,800-patient Phase 3 after strong 48-week MASH data
Altimmune entered 2026 with a new CEO and a tight focus on advancing pemvidutide, its dual glucagon/GLP-1 liver-directed candidate. Management reported 48-week Phase 2 MASH data showing early MASH res...
- New CEO Jerry Durso joined in January and is prioritizing pemvidutide as a late-stage, liver-focused program.
- Pemvidutide received FDA Breakthrough Therapy designation in MASH, recognizing preliminary evidence of substantial improvement over available therapies.
- Phase 2 IMPACT data: pemvidutide showed early MASH resolution at 24 weeks and clear anti-fibrotic signals at 48 weeks, with non-invasive tests such as ELF and liver stiffness improving, especially at 1.8 mg.
- +11 more takeaways